STAT+: Regeneron’s Eylea sales dip, as competition looms
The “meaningful Eylea miss could potentially foreshadow biosimilar challenges,” an analyst said about Regeneron’s drug.
News
#JPM23 in review, the year ahead, & the merits of Miami
What happened at #JPM23, biotech’s big reunion? Will this year be better than the last? And is it time to quit San Francisco? All that and more on the latest… […]
News
STAT+: Kite to buy Tmunity Therapeutics, Carl June’s troubled CAR-T startup
Kite’s two recent deals represent notable investments in a type of CAR-T that some had thought may become obsolete. […]
News
STAT+: Money troubles and M&A: What’s on biotech insiders’ minds ahead of a not-so-celebratory JPM week
Nearly 70% of biotech insiders say financing — such as raising venture capital or launching an IPO — will be a challenge in 2023. […]
